Vir Biotechnology, Inc.

NASDAQ:VIR

10.5 (USD) • At close January 15, 2025
Bedrijfsnaam Vir Biotechnology, Inc.
Symbool VIR
Munteenheid USD
Prijs 10.5
Beurswaarde 1,446,060,000
Dividendpercentage 0%
52-weken bereik 6.56 - 14.45
Industrie Biotechnology
Sector Healthcare
CEO Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Website https://www.vir.bio

An error occurred while fetching data.

Over Vir Biotechnology, Inc.

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza

Vergelijkbare Aandelen

Patterson Companies, Inc. logo

Patterson Companies, Inc.

PDCO

30.89 USD

Karuna Therapeutics, Inc. logo

Karuna Therapeutics, Inc.

KRTX

329.83 USD

GoodRx Holdings, Inc. logo

GoodRx Holdings, Inc.

GDRX

4.35 USD

Certara, Inc. logo

Certara, Inc.

CERT

11.96 USD

Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc.

MRTX

58.7 USD

Progyny, Inc. logo

Progyny, Inc.

PGNY

20.75 USD

Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

NTLA

9.71 USD

Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

RARE

40.98 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)